A61K9/0024

Hydrogels based on functionalized polysaccharides

The present invention relates to functionalized hydrogel networks grafted with at least one moiety for use in numerous fields, from cosmetics to surgery and medicine.

IN-VIAL DEPOSITION OF A STABLE, STERILE AND CRYSTALLINE O-ACETYL SALICYLIC ACID (ASPIRIN)
20220409636 · 2022-12-29 · ·

Improved, stable aspirin formulations for intravenous use are disclosed. Methods of lyophilizing the aspirin from bulk solutions as well as kits containing the lyophilized aspirin and methods of treatment using the same are also disclosed.

DOSAGE FORM FOR EXTENDED RELEASE OF AN ANTIBODY OR LARGE PROTEIN

The present disclosure relates to dosage forms for extended release of an antibody or large protein. The extended release dosage forms comprise a biodegradable multi-block copolymer matrix and provide for extended release of antibody or large protein over a desired time period.

TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID

Provided is a transplantation device comprising a hydrogel in which insulin-secreting cells or pancreatic islets are enclosed, wherein the hydrogel is prepared by gelatinizing an alginic acid derivative by a chemical crosslinkage. Thus, a novel transplantation device is provided.

CELL DELIVERY ARTICLES AND METHODS OF ADMINISTRATION
20220409525 · 2022-12-29 · ·

This application relates to cell delivery articles and methods for delivering cells into the body in a manner that allows them to incorporate into surrounding tissue and express cell products. The cell delivery articles are generally capable of maintaining viability of the cells for a period of time that allows such incorporation to occur. Additionally, a cell delivery article may include a bio-ghost coating that prevents the cell delivery article from being recognized by the immune system, and/or minimizes or prevents development of fibrotic tissue which can interfere with nutrients and oxygen entering the cell delivery article and reaching the cells. A cell delivery article may be formulated for delivery by various routes of administration.

Thermo-responsive hydrogel for intratumoral administration as a treatment in solid tumor cancers

A room temperature injectable thermo-responsive hydrogel comprises a P407 poloxamer base hydrogel, chitosan, 2-Hydroxypropyl β-cyclodextrin and genipin. The chitosan and genipin form an interpenetrating scaffold within the hydrogel in which the chitosan is crosslinked with genipin. Chemotherapeutic drugs can be added to the hydrogel singly or in combination in effective amounts without any loss of thermo-responsiveness in the hydrogel. Therapeutic use of the thermo-responsive hydrogel in the intratumoural treatment of solid cancer is also described.

Fluid delivery device with hydrophobic surface

Embodiments of the present invention are directed to a liquid delivery apparatus. A non-limiting example of the apparatus includes a substrate including a cavity formed in a surface of the substrate. The apparatus can also include a membrane disposed on the surface of the substrate covering an opening of the cavity. The apparatus can also include a hydrophobic layer disposed on the membrane. The apparatus can also include a seal disposed between the membrane and the substrate, wherein the seal surrounds the opening of the cavity. The apparatus can also include an electrode layer coupled to the membrane.

THIOL-MODIFIED HYALURONAN AND HYDROGEL COMPRISING THE CROSSLINKED HYALURONAN
20220403054 · 2022-12-22 ·

A thiol-modified hyaluronan, wherein the thiol-modified hyaluronan comprises a plurality of modification groups with a thiol-group in the hyaluronan side-chains, wherein the modification group comprises an amino acid residue with basic side chain and a conjugated terminal naturally occurring amino-thiol as well as a sterile hydrogel composition comprising a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of the thiol-modified hyaluronan and uses of the composition.

COMPOSITIONS AND METHODS FOR CANCER TREATMENT BY ENHANCING ANTITUMOR IMMUNITY USING TANNIC ACID-BASED NANOCAPSULES
20220401374 · 2022-12-22 · ·

The present disclosure generally relates to a composition matter and a method for cancer treatment comprising albumin (alb) coated tannic acid-Fe nanoparticles (NPs) with a therapeutic compound, and one or more diluents, excipients or carriers. In particular, the present invention provides a treatment by enhancing antitumor immunity using tannic acid-based nanoparticles containing a therapeutic cancer treatment that can induce immunogenic cell death (ICD). The method disclosed herein provides a potential solution to the immunotoxicity accompanying the ICD cancer immunotherapy by intratumoral or intravenous administration of a nanocapsule formulation of carfilzomib (CFZ), an ICD-inducing proteasome inhibitor, using interfacial supramolecular assembly of tannic acid (TA) and iron, supplemented with albumin coating for better metabolic stability.

ADHESIVE COMPOSITIONS COMPRISING THERAPEUTICS
20220401617 · 2022-12-22 ·

Compositions may include a therapeutic that is released from the composition to treat any number of ailments or conditions (e.g., pain, infection, cancer, osteoporosis) or to help accelerate local tissue regeneration (e.g., growth hormone, bone morphogenic protein) or to assist with surgical or therapeutic treatment (e.g., imaging modality), or any of a combination thereof.